Q-omics provides the consensus-scored ANTXR2 profile across patient tissues and cancer cell-line models. ANTXR2 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ANTXR2 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ANTXR2 RNA expression shows 25,549 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where ANTXR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANTXR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANTXR2 survival associations across molecular data types. ANTXR2 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANTXR2 RNA expression–survival associations across cancer types. High ANTXR2 expression shows unfavorable associations in MESO, LGG, ACC and HNSC, but favorable associations in KIRC and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify MESO as the clearest survival context for ANTXR2 RNA expression.
This table summarizes ANTXR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ANTXR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANTXR2 shows lower tumor expression in BLCA, COAD, KIRP and THCA and higher tumor expression in HNSC and KIRC. The HNSC box plot shows higher ANTXR2 RNA expression in tumor versus normal tissue (log2 FC = +2.383, t-test p < 0.001).
This table shows molecular features associated with ANTXR2 in patient tissues and cancer cell lines. In patient samples, ANTXR2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANTXR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
